Third Quarter 2019 Results

Bayer AG News Conference Call

Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health

Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros
EBITDA before special items advances by 7.5 percent to 2.291 billion euros
Crop Science reports higher sales and substantial earnings growth
Pharmaceuticals increases sales – earnings decline due to one-time income in prior year
Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings
Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year
Core earnings per share up by 6.4 percent to 1.16 euros
Group outlook confirmed and aligned to continuing operations

Links

Quarterly Statement Q3 2019

Speaker